Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study (Q33428297)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study |
scientific article |
Statements
1 reference
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study (English)
1 reference
Michael Hallek
1 reference
Sebastian Grosicki
1 reference
Asher Chanan-Khan
1 reference
Paula Cramer
1 reference
Fatih Demirkan
1 reference
Graeme Fraser
1 reference
Rodrigo Santucci Silva
1 reference
Aleksander Pristupa
1 reference
Ann Janssens
1 reference
Jiri Mayer
1 reference
Marie-Sarah Dilhuydy
1 reference
Halyna Pylypenko
1 reference
Javier Loscertales
1 reference
Abraham Avigdor
1 reference
Simon Rule
1 reference
Diego Villa
1 reference
Olga Samoilova
1 reference
Panagiots Panagiotidis
1 reference
Andre Goy
1 reference
Anthony Mato
1 reference
Miguel A Pavlovsky
1 reference
Claes Karlsson
1 reference
Michelle Mahler
1 reference
Mariya Salman
1 reference
Steven Sun
1 reference
Charles Phelps
1 reference
Sriram Balasubramanian
1 reference
Angela Howes
1 reference
HELIOS investigators
1 reference
4 December 2015
1 reference
1 reference
Identifiers
1 reference